306 research outputs found
Chaos in free electron laser oscillators
The chaotic nature of a storage-ring Free Electron Laser (FEL) is
investigated. The derivation of a low embedding dimension for the dynamics
allows the low-dimensionality of this complex system to be observed, whereas
its unpredictability is demonstrated, in some ranges of parameters, by a
positive Lyapounov exponent. The route to chaos is then explored by tuning a
single control parameter, and a period-doubling cascade is evidenced, as well
as intermittence.Comment: Accepted in EPJ
Extreme Ultraviolet (EUV) Sources for Lithography based on Synchrotron Radiation
The study presented here was initiated by a discussion to investigate the
possibility of using synchrotron radiation as a source for the Next Generation
Lithography (NGL) based on the EUV-concept (Extreme Ultra-Violet; here 13.5 nm
or 11.3 nm radiation, respectively). The requirements are: 50 W, 2% bandwidth
and minimal power outside this bandwidth. Three options were investigated. The
first two deal with radiation from bending magnets and undulators. The results
confirm the earlier work by Oxfords Instrument and others that these
light-sources lack in-band power while emitting excessive out-of-band
radiation. The third approach is a FEL (Free Electron Laser) driven by a 500
MeV linear accelerator with a superconducting mini-undulator as radiation
emitting device. Such a device would produce in-band EUV-power in excess of 50
W with negligible out-of-band power.Comment: Submitted to Nuclear Instruments and Methods
Intracerebral delivery of Carboplatin in combination with either 6 MV Photons or monoenergetic synchrotron X-rays are equally efficacious for treatment of the F98 rat glioma.
International audienceABSTRACT: BACKGROUND: The purpose of the present study was to compare side-by-side the therapeutic efficacy of a 6-day infusion of carboplatin, followed by X-irradiation with either 6 MV photons or synchrotron X-rays, tuned above the K-edge of Pt, for treatment of F98 glioma bearing rats. METHODS: Carboplatin was administered intracerebrally (i.c.) to F98 glioma bearing rats over 6 days using AlzetTM osmotic pumps starting 7 days after tumor implantation. Radiotherapy was delivered in a single 15 Gy fraction on day 14 using a conventional 6 MV linear accelerator (LINAC) or 78.8 keV synchrotron X-rays. RESULTS: Untreated control animals had a median survival time (MeST) of 33 days. Animals that received either carboplatin alone or irradiation alone with either 78.8 keV or 6 MV had a MeSTs 38 and 33 days, respectively. Animals that received carboplatin in combination with X-irradiation had a MeST of > 180 days with a 55% cure rate, irrespective of whether they were irradiated with either 78.8 KeV synchrotron X-rays or 6MV photons. CONCLUSIONS: These studies have conclusively demonstrated the equivalency of i.c. delivery of carboplatin in combination with X-irradiation with either 6 MV photons or synchrotron X-rays
Intracerebral delivery of 5-iodo-2'-deoxyuridine in combination with synchrotron stereotactic radiation for the therapy of the F98 glioma.
International audienceIodine-enhanced synchrotron stereotactic radiotherapy takes advantage of the radiation dose-enhancement produced by high-Z elements when irradiated with mono-energetic beams of synchrotron X-rays. In this study it has been investigated whether therapeutic efficacy could be improved using a thymidine analogue, 5-iodo-2'-deoxyuridine (IUdR), as a radiosentizing agent. IUdR was administered intracerebrally over six days to F98 glioma-bearing rats using Alzet osmotic pumps, beginning seven days after tumor implantation. On the 14th day, a single 15 Gy dose of 50 keV synchrotron X-rays was delivered to the brain. Animals were followed until the time of death and the primary endpoints of this study were the mean and median survival times. The median survival times for irradiation alone, chemotherapy alone or their combination were 44, 32 and 46 days, respectively, compared with 24 days for untreated controls. Each treatment alone significantly increased the rats' survival in comparison with the untreated group. Their combination did not, however, significantly improve survival compared with that of X-irradiation alone or chemotherapy alone. Further studies are required to understand why the combination of chemoradiotherapy was no more effective than X-irradiation alone
Synchrotron radiation-based experimental determination of the optimal energy for cell radiotoxicity enhancement following photoelectric effect on stable iodinated compounds
This study was designed to experimentally evaluate the optimal X-ray energy for increasing the radiation energy absorbed in tumours loaded with iodinated compounds, using the photoelectric effect. SQ20B human cells were irradiated with synchrotron monochromatic beam tuned at 32.8, 33.5, 50 and 70 keV. Two cell treatments were compared to the control: cells suspended in 10 mg ml1 of iodine radiological contrast agent or cells pre-exposed with 10 mM of iodo-desoxyuridine (IUdR) for 48 h. Our radiobiological end point was clonogenic cell survival. Cells irradiated with both iodine compounds exhibited a radiation sensitisation enhancement. Moreover, it was energy dependent, with a maximum at 50 keV. At this energy, the sensitisation calculated at 10% survival was equal to 2.03 for cells suspended in iodinated contrast agent and 2.60 for IUdR. Cells pretreated with IUdR had higher sensitisation factors over the energy range than for those suspended in iodine contrast agent. Also, their survival curves presented no shoulder, suggesting complex lethal damages from Auger electrons. Our results confirm the existence of the 50 keV energy optimum for a binary therapeutic irradiation based on the presence of stable iodine in tumours and an external irradiation. Monochromatic synchrotron radiotherapy concept is hence proposed for increasing the differential effect between healthy and cancerous tissue irradiation
An optimized architecture of a digital filtering integrated procesor, and efficiency graphical valuation
This paper deals with the optimization of a digital signal processor's architecture. We define the notion of silicon
area temporal utilization efficiency and calculate it with a graphie method . Using benchmark algorithm (Fast Fourier
Transform butterfly) we estimate the influence of an architecture choice on its efficiency . In this manner we can
objectively measure the contribution of the multifarious modifications .Conception d'un processeur pour filtrage numérique et optimisation de son architecture. Définition de la notion de rendement temporel d'utilisation de la surface de silicium, mesure par méthode graphique. A partir du choix d'une jauge d'algorithme, le papillon de la transformée de Fourier rapide on évalue l'influence de tel choix d'architecture sur les performances et le rendement. On essaye de valider la structure indépendamment de la technologi
Towards in vivo dosimetry for contrast enhanced synchrotron stereotactic radiation therapy based on iodine x-ray spectroscopy
The first trial applications of Contrast-Enhanced Synchrotron Stereotactic Radiation Therapy (SSRT) is underway since June 2012 at the European Synchrotron Radiation Facility (ESRF) in Grenoble (France). The phase I-II clinical trial is designed to test the feasibility and safety of SSRT through a dose escalation protocol. Contrast enhanced radiotherapy achieves localized dose enhancement due to higher photoelectric effect rate in the target. This increase is obtained through the preferential uptake of high-Z media (iodine) in the tumoral area combined with irradiations with medium energy synchrotron x-rays. In vivo dosimetry (i.e. experimental dosimetry in real time during the treatment) would be a serious added value to the project, in terms of online dose monitoring and quality control. It is challenging to perform in vivo dosimetry with the currently available conventional clinical techniques. In this work we investigated a method using x-ray fluorescence detection to derive the iodine concentration contained in a tumor during the treatment of a patient, as a first step towards in vivo dosimetry. A mean iodine concentration of 0.33 ± 0.22 mg/ml has been retrieved in the tumor of the patient compared to 2 mg/ml expected would correspond to 3% local dose enhancement in the tumor. Further work will be performed to improve the attenuation correction method. The expected amount of iodine should be 2 mg/ml in the tumor (20% dose enhancement). This method is suitable to detect iodine in the target but has some problem in quantifying the real amount of iodine present during the irradiation
- …